Supreme Court Questions Whether 510(k) "Intended Use" Must Be Bona Fide
This article was originally published in The Gray Sheet
Executive Summary
The "intended use" statement in a 510(k) is "not a factual representation" of how a device will be used on the market, Kenneth Geller, attorney for the Buckman Co., contended before the U.S. Supreme Court Dec. 4.
You may also be interested in...
Supreme Court Leaves FDA To Its Own Devices In Regulating Fraud Claims
The Supreme Court's Feb. 21 decision in Buckman Co. v. Plaintiffs Legal Committee defends off-label use as a vital "corollary" to FDA's regulatory scheme, while also investing sole authority in the agency to determine whether premarket submissions are fraudulent.
Supreme Court Leaves FDA To Its Own Devices In Regulating Fraud Claims
The Supreme Court's Feb. 21 decision in Buckman Co. v. Plaintiffs Legal Committee defends off-label use as a vital "corollary" to FDA's regulatory scheme, while also investing sole authority in the agency to determine whether premarket submissions are fraudulent.
Buckman Case Testimony At Odds With FDA Pedicle Screw Enforcement
A ruling by the U.S. Supreme Court in the pedicle screw case, Buckman Co. v. Plaintiffs' Legal Committee, could influence FDA's enforcement of 21 CFR 801.4 for manufacturers that are aware of off-label use with their products.